Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2018 12:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular Diseases

PARIS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in the development of drug candidates to treat the disabilities...
October 22, 2018 13:56 ET | Source: BIOPHYTIS SA

BIOPHYTIS : Interim Results 2018 and Perspective on Activity

PARIS, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to fight age-related degenerative...
September 13, 2018 12:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS Obtains a €10 Million Loan With Kreos Capital

The funding will serve for the development of BIOPHYTIS Inc. in Boston and the preparation of MYODA clinical program in Duchenne myopathy PARIS, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS...
September 04, 2018 01:30 ET | Source: BIOPHYTIS SA

BIOPHYTIS Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia

Over 200 patients recruited in the SARA-OBS study with the majority of patients enrolled from the U.S. and Belgium 60 patients ready to enter the SARA-INT trial PARIS, Sept. 04, 2018 (GLOBE...
May 24, 2018 12:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia

Preliminary results expected in Q3 2019 PARIS, May 24, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug...
May 15, 2018 14:22 ET | Source: BIOPHYTIS SA

BIOPHYTIS Receives Orphan Drug Designation in the United States for Sarconeos in Duchenne Muscular Dystrophy (DMD)

PARIS, May 15, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related degenerative...
March 28, 2018 08:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS: 2017 Full Year Results

Launch and progress in the SARA-OBS observational clinical study in the United States, Belgium, France, and Italy;Agencies’ authorizations of SARA-INT phase 2b interventional clinical study in the...
March 20, 2018 15:36 ET | Source: BIOPHYTIS SA

BIOPHYTIS files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD)

Presentation of MYODA: a new clinical program in the treatment of Duchenne Muscular Dystrophy PARIS, March 20, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology...
March 01, 2018 02:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Additional data confirm the relevance of the protocol and the compound in the clinical study SARA-INT phase 2B PARIS, March 01, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a...
December 19, 2017 01:45 ET | Source: BIOPHYTIS SA

BIOPHYTIS to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018

PARIS, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...